Sutimlimab shows promise for hard-to-treat, rare blood disorder
- Details
- Category: Research
In a first-in-human clinical trial reported today in Blood, the investigational drug sutimlimab appeared to be effective in treating cold agglutinin disease, a rare chronic blood disorder for which there are currently no approved treatments. Cold agglutinin disease is caused by a malfunction in the immune system that causes antibodies - components of the immune system that are produced in the blood and help the body fight off disease - to mistakenly latch onto and kill red blood cells.
First line immunotherapy combination fails to improve overall survival in lung cancer
- Details
- Category: Research
First line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial presented at the ESMO Immuno-Oncology Congress.(1) The combination of immune checkpoint inhibitors and chemotherapy has been successfully tested in different trials as first line therapy for
Helping the anti-parasitic medicine go down
- Details
- Category: Research
Scientists have developed a new way to deliver anti-parasitic medicines more efficiently. An international team, led by Professor Francisco Goycoolea from the University of Leeds and Dr Claudio Salomon from the Universidad Nacional de Rosario, Argentina, and in collaboration with colleagues at the University of Münster, Germany, have developed a novel pharmaceutical formulation to administer triclabendazole - an anti-parasitic drug used to treat a type of flatworm infection - in billions of tiny capsules.
Scientists pave the way for saliva test for Alzheimer's disease
- Details
- Category: Research
University of Alberta scientists have identified three biomarkers for detecting mild cognitive impairment and Alzheimer's disease in saliva samples. The research has promising results for application in a clinical setting. The research team combines expertise in metabolomics from Liang Li, professor in the Department of Chemistry, and neurodegenerative disorders from Roger Dixon, professor in the Department of Psychology.
Drug cocktail turns off the juice to cancer cells
- Details
- Category: Research
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth - this was discovered by researchers from the University of Basel's Biozentrum two years ago. In a follow-up study, recently published in Cell Reports, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
MIT engineers repurpose wasp venom as an antibiotic drug
- Details
- Category: Research
The venom of insects such as wasps and bees is full of compounds that can kill bacteria. Unfortunately, many of these compounds are also toxic for humans, making it impossible to use them as antibiotic drugs. After performing a systematic study of the antimicrobial properties of a toxin normally found in a South American wasp, researchers at MIT have now created variants of the peptide that are potent against bacteria but nontoxic to human cells.
Statins overprescribed for primary prevention
- Details
- Category: Research
Even healthy people who don't suffer from a cardiovascular disease are prescribed cholesterol-lowering drugs, known as statins, if they meet certain risk criteria. However, for years the use of statins for primary prevention has been hotly debated among experts. "Ultimately, this measure helps to prevent heart attacks or strokes in only a few cases. But all people who take statins are at risk of experiencing the side effects," says Milo Puhan, professor of epidemiology and public health at the University of Zurich.
More Pharma News ...
- Cannabis-based compound may reduce seizures in children with epilepsy
- New Parkinson's disease drug target revealed through study of fatty acids
- CAR-T cell update: Therapy improves outcomes for patients with B-cell lymphoma
- When good macrophages go bad
- 91 percent response rate for venetoclax against newly diagnosed AML in older adults
- New technique for identifying small molecules may speed up drug discovery, manufacturing
- Some research may be encouraging ineffective prescriptions